Litigation Details for Cumberland Pharmaceuticals v. Mylan Institutional LLC (Fed. Cir. 2015)

« Back to Dashboard

Cumberland Pharmaceuticals v. Mylan Institutional LLC (Fed. Cir. 2015)

Docket		Date Filed	2015-11-03
Court	Court of Appeals for the Federal Circuit	Date Terminated	2017-01-26
Cause		Assigned To
Jury Demand		Referred To
Patents	8,148,356
Link to Docket	External link to docket

Details for Cumberland Pharmaceuticals v. Mylan Institutional LLC (Fed. Cir. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-03				External link to document

Cumberland Pharmaceuticals v. Mylan Institutional LLC, 16-1155: Litigation Summary and Patent Analysis

Last updated: November 9, 2026

Cumberland Pharmaceuticals prevailed in the Federal Circuit appeal concerning U.S. Patent No. 8,399,445, which covered the sulfite-free acetylcysteine formulation used in Cumberland’s Acetadote product. The court affirmed the district court’s judgment that Mylan’s proposed generic product infringed asserted claims and that the claims were not invalid for obviousness. The decision limited immediate ANDA-based generic entry and validated Cumberland’s formulation patent strategy. Cumberland Pharms. Inc. v. Mylan Institutional LLC, 846 F.3d 1213 (Fed. Cir. 2017).

What patents protected Cumberland’s Acetadote product?

The principal patent in the litigation was U.S. Patent No. 8,399,445, assigned to Cumberland Pharmaceuticals Inc. The patent concerned acetylcysteine formulations that avoided sulfite preservatives and included a chelating agent, particularly EDTA or edetate disodium.

Item	Detail
Brand	Acetadote
Active ingredient	Acetylcysteine
Dosage form	Intravenous injection
Patent	U.S. Patent No. 8,399,445
Patent holder	Cumberland Pharmaceuticals Inc.
Defendant	Mylan Institutional LLC
Appeal number	Federal Circuit No. 16-1155
Decision	February 21, 2017
Reported citation	846 F.3d 1213
Primary issue	Obviousness and infringement of formulation claims

The asserted claims covered compositions containing acetylcysteine and a chelating agent, with the formulation substantially free of sulfites. The claimed formulation addressed stability and discoloration problems associated with acetylcysteine solutions.

Acetadote was approved by the FDA as an intravenous acetylcysteine product for the treatment of acetaminophen overdose. The product replaced older acetylcysteine formulations that used sulfite-containing excipients and were associated with adverse reactions.

What was the procedural history in Cumberland v. Mylan?

Mylan submitted an abbreviated new drug application seeking FDA approval for a generic acetylcysteine injection. Mylan’s ANDA included a Paragraph IV certification challenging Cumberland’s patent rights.

Cumberland filed a patent-infringement action in the U.S. District Court for the District of Delaware. The filing triggered the Hatch-Waxman statutory stay, which generally prevents FDA approval of the ANDA for up to 30 months unless the litigation is resolved earlier.

The district court ruled for Cumberland after a bench trial. It found that Mylan’s proposed product would infringe the asserted claims of the ’445 patent and that the claims were not invalid for obviousness. Mylan appealed to the U.S. Court of Appeals for the Federal Circuit.

The Federal Circuit affirmed the district court’s judgment. The reported decision did not create a new patent infringement test, but it applied established obviousness principles to a pharmaceutical formulation where the claimed excipient combination produced improved stability.

Why did the Federal Circuit reject Mylan’s obviousness challenge?

Mylan argued that the claimed formulation would have been obvious based on prior art disclosing acetylcysteine, injectable formulations, chelating agents, and methods for addressing oxidation or discoloration.

The Federal Circuit rejected the challenge because the record supported the district court’s finding that a skilled artisan would not have had a sufficient reason to combine the relevant prior-art teachings with a reasonable expectation of success.

The court focused on several factors:

1. The prior art did not establish that the specific combination would reliably solve the formulation problem.
2. The claimed formulation produced unexpected stability benefits.
3. The prior art contained competing formulation approaches and did not provide a clear path toward the patented composition.
4. Cumberland presented evidence linking the invention to commercial Acetadote performance.
5. Mylan did not show that routine experimentation would have predictably produced the claimed formulation.

The Federal Circuit treated objective indicia of nonobviousness as part of the overall obviousness analysis rather than as a secondary issue. The evidence included unexpected results and commercial success. The court agreed that these considerations supported patentability when evaluated with the prior-art record.

What role did unexpected results play?

Unexpected results were central to Cumberland’s defense of the ’445 patent. The evidence showed that the claimed formulation improved the stability of acetylcysteine without relying on sulfite preservatives.

Mylan argued that the claimed excipients were individually known. The Federal Circuit’s analysis reflected the principle that known components do not automatically make a combination obvious. The relevant question was whether the prior art would have led a skilled artisan to select and combine those components with a reasonable expectation that the resulting formulation would perform as claimed.

The decision therefore has continuing relevance for pharmaceutical formulation patents. A patent owner can strengthen a formulation case by documenting:

• A defined stability or degradation problem.
• The shortcomings of known excipients.
• The unpredictability of excipient selection.
• Comparative stability data.
• Unexpected performance relative to the closest prior art.
• Evidence tying the claimed formulation to commercial uptake.

What infringement issues were decided?

Mylan’s ANDA product was treated as a proposed commercial product for purposes of Hatch-Waxman infringement. Cumberland alleged that the generic formulation would meet the limitations of the asserted claims.

The litigation did not involve ordinary marketplace sales by Mylan. Instead, the alleged infringement arose from Mylan’s submission of an ANDA under 35 U.S.C. § 271(e)(2), which creates an artificial act of infringement for certain patent disputes involving a proposed generic drug.

The district court found infringement, and Mylan’s appeal focused primarily on validity. The Federal Circuit affirmed the judgment supporting Cumberland’s patent rights.

The case illustrates the importance of the product-specific ANDA record. In pharmaceutical litigation, infringement may turn on:

• The active ingredient concentration.
• The identity and amount of excipients.
• Preservative content.
• pH and formulation conditions.
• Manufacturing specifications incorporated into the ANDA.
• Proposed labeling and method-of-use language.

What was the FDA and Orange Book status of Acetadote?

Acetadote is an FDA-approved acetylcysteine injection product. Cumberland’s patent rights were enforced through the Hatch-Waxman framework, which connects FDA approval, Orange Book listing, Paragraph IV certifications, and patent litigation.

The relevant regulatory structure was:

Regulatory event	Consequence
Acetadote approval	Established the reference listed drug for generic applications
Orange Book patent listing	Required ANDA applicants to address listed patent claims
Mylan Paragraph IV certification	Asserted that the listed patent was invalid, unenforceable, or not infringed
Cumberland’s timely lawsuit	Triggered the statutory approval stay
District court judgment	Preserved the patent barrier against Mylan’s proposed product
Federal Circuit affirmance	Left the judgment intact

The Orange Book is the controlling source for current listed-patent status and expiration information. The litigation decision itself establishes the adjudicated validity and infringement outcome for the asserted claims, but it does not by itself provide a current Orange Book status report.

When does the Acetadote patent lose exclusivity?

The ’445 patent had a statutory term based on its nonprovisional filing date, subject to patent-term adjustment and any applicable regulatory or pediatric extensions. The exact effective expiration date must be determined from the current USPTO patent record and FDA Orange Book listing.

The 2017 Federal Circuit decision did not extend the patent term. It confirmed the enforceability of the patent during the disputed ANDA period.

Generic entry could occur through several routes:

1. Expiration of the relevant patent term.
2. A successful later validity or noninfringement challenge.
3. A settlement permitting an agreed launch date.
4. A license from Cumberland.
5. FDA approval after all statutory patent barriers expired.

The Federal Circuit ruling reduced the probability of immediate Mylan entry but did not eliminate later generic competition after patent expiration or a separate successful challenge.

Which companies challenged Cumberland’s Acetadote patent?

Mylan Institutional LLC was the defendant and ANDA challenger in the reported appeal. The case involved a Paragraph IV challenge to Cumberland’s listed patent rights.

The appellate record identified Mylan’s principal theories as:

• The asserted claims were obvious over the prior art.
• The claimed excipient combination was predictable.
• The prior art provided a reason to combine known formulation components.
• The objective evidence did not overcome the prima facie obviousness case.

The Federal Circuit rejected those arguments on the record developed in the district court.

No separate biosimilar pathway was implicated. Acetylcysteine is a small-molecule active ingredient, so competing products proceed through the ANDA pathway rather than the abbreviated biologics license application pathway under the Biologics Price Competition and Innovation Act.

How strong was Cumberland’s patent estate?

The litigated patent had meaningful strength in three areas:

Formulation protection

The ’445 patent protected a specific pharmaceutical formulation rather than merely the acetylcysteine molecule. Formulation patents can remain commercially important after compound-level exclusivity expires because a generic applicant must either design around the formulation or challenge the patent.

Evidence of technical benefit

Cumberland supported the claims with stability evidence and evidence that the formulation solved a practical problem involving acetylcysteine degradation and sulfite-free administration.

Successful appellate defense

The Federal Circuit’s affirmance materially strengthened Cumberland’s position against the specific Mylan ANDA. The ruling did not guarantee that every later generic formulation would infringe, but it confirmed that the asserted claims survived the obviousness challenge presented in this case.

Patent strength remained constrained by the narrow scope of formulation claims. A competitor could potentially avoid infringement by changing:

• The chelating agent.
• Excipient concentrations.
• Preservative systems.
• Formulation pH.
• Container or packaging conditions.
• Manufacturing parameters, if those limitations were outside the claims.

What generic entry risks existed after the decision?

The litigation reduced immediate entry risk from Mylan but left several long-term risks:

Risk	Assessment
Mylan entry before patent expiry	Reduced after Federal Circuit affirmance
Entry by a redesigned formulation	Possible if the design avoided the asserted claim limitations
Additional Paragraph IV challenges	Possible from other ANDA applicants
Post-expiration generic entry	Expected once relevant patents and exclusivity barriers expired
Biosimilar competition	Not applicable
Manufacturing workaround	Possible if stability could be achieved without the patented combination
Patent-term uncertainty	Dependent on USPTO and FDA records
Settlement-based launch	Possible if Cumberland and a challenger reached an agreement

The most important commercial risk was not biosimilar substitution but formulation design-around. The product’s active ingredient was well known. Cumberland’s defensible value therefore depended on the technical and legal breadth of the formulation claims.

Did Cumberland and Mylan reach a settlement?

The Federal Circuit decision reports an adjudicated appeal and affirmance. It does not establish a later commercial settlement or authorized generic arrangement. A settlement would have to be evaluated from subsequent court filings, SEC disclosures, FDA records, or other transaction-specific sources.

The 2017 appellate outcome itself was a judgment in Cumberland’s favor, not a reported settlement disposition.

What was the commercial significance of the ruling?

The ruling protected Cumberland’s Acetadote franchise against the challenged Mylan ANDA during the remaining enforceable patent period. It supported continued sales of the branded product and preserved the value of Cumberland’s formulation-based exclusivity.

Revenue exposure depended on:

• Acetadote net sales.
• The duration of the remaining patent term.
• The number and timing of competing ANDAs.
• The ability of competitors to design around the ’445 patent.
• Hospital purchasing behavior.
• Contracting and formulary substitution.
• The availability of alternative acetylcysteine products.

The decision did not establish a permanent monopoly over acetylcysteine. It protected a particular formulation and limited the specific generic product challenged by Cumberland.

How does Cumberland v. Mylan compare with typical pharmaceutical patent litigation?

The case follows a standard Hatch-Waxman pattern but has a formulation-specific validity profile.

Issue	Cumberland v. Mylan	Typical small-molecule case
Regulatory pathway	ANDA	ANDA
Challenge	Paragraph IV	Paragraph IV
Patent type	Formulation	Compound, formulation, method, or polymorph
Infringement theory	Proposed ANDA product	Proposed ANDA product
Main validity issue	Obviousness	Often obviousness or written description
Evidence emphasized	Stability and unexpected results	Clinical, chemical, or formulation evidence
Biosimilar issues	None	None for small molecules
Commercial barrier	Patent term and formulation scope	Patent and regulatory exclusivity

The case is particularly relevant where a drug’s active ingredient is old but the marketed product depends on a technically improved formulation.

Key Takeaways

• Cumberland’s principal litigated patent was U.S. Patent No. 8,399,445.
• The patent covered a sulfite-free acetylcysteine formulation containing a chelating agent.
• Mylan challenged the patent through a Paragraph IV ANDA certification.
• The district court found infringement and rejected Mylan’s obviousness defense.
• The Federal Circuit affirmed in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC, 846 F.3d 1213 (Fed. Cir. 2017).
• Unexpected stability results and commercial evidence supported nonobviousness.
• The case involved a small-molecule ANDA, not a biosimilar application.
• The ruling blocked the specific Mylan challenge during the relevant patent period but did not prevent later design-arounds or post-expiration generic entry.
• Current patent expiration and Orange Book status must be determined from the latest USPTO and FDA records.

FAQs About Cumberland Pharmaceuticals v. Mylan

What drug was at issue in Cumberland v. Mylan?

The case involved Acetadote, Cumberland’s intravenous acetylcysteine product used to treat acetaminophen overdose.

Was the Cumberland Acetadote patent invalidated?

No. The Federal Circuit affirmed the judgment rejecting Mylan’s obviousness challenge to the asserted claims of U.S. Patent No. 8,399,445.

Was Mylan’s generic approved after the appeal?

The appellate decision does not establish that Mylan’s proposed product received FDA approval or entered the market.

Did the case involve a method-of-use patent?

The central dispute concerned formulation claims covering acetylcysteine, a chelating agent, and the absence of sulfite preservatives. It was principally a formulation-patent dispute.

Can another generic company avoid the Cumberland patent?

Potentially. A competitor could pursue a formulation that does not satisfy one or more limitations of the asserted claims, subject to FDA requirements, infringement analysis, and any other listed patents.

References

1. Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC, 846 F.3d 1213 (Fed. Cir. 2017).

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,399,445. Patent Center.